ES3005482T3 - A complex of a glucopyranosyl derivative and preparation method and use thereof - Google Patents

A complex of a glucopyranosyl derivative and preparation method and use thereof Download PDF

Info

Publication number
ES3005482T3
ES3005482T3 ES16868062T ES16868062T ES3005482T3 ES 3005482 T3 ES3005482 T3 ES 3005482T3 ES 16868062 T ES16868062 T ES 16868062T ES 16868062 T ES16868062 T ES 16868062T ES 3005482 T3 ES3005482 T3 ES 3005482T3
Authority
ES
Spain
Prior art keywords
complex
inhibitor
crystal
crystalline form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16868062T
Other languages
English (en)
Spanish (es)
Inventor
Pengcho Tang
Zheng Gu
Wuyong Wu
Zongyuan Zhang
Panpan Kang
Tong Qu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Application granted granted Critical
Publication of ES3005482T3 publication Critical patent/ES3005482T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
ES16868062T 2015-11-27 2016-11-28 A complex of a glucopyranosyl derivative and preparation method and use thereof Active ES3005482T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510851466 2015-11-27
PCT/CN2016/107543 WO2017088839A1 (en) 2015-11-27 2016-11-28 A complex of a glucopyranosyl derivative and preparation method and use thereof

Publications (1)

Publication Number Publication Date
ES3005482T3 true ES3005482T3 (en) 2025-03-14

Family

ID=58763019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16868062T Active ES3005482T3 (en) 2015-11-27 2016-11-28 A complex of a glucopyranosyl derivative and preparation method and use thereof

Country Status (8)

Country Link
US (1) US10555930B2 (enExample)
EP (1) EP3371199B1 (enExample)
JP (1) JP6916180B2 (enExample)
CN (1) CN106810582B (enExample)
AU (1) AU2016360634B2 (enExample)
CA (1) CA3005920C (enExample)
ES (1) ES3005482T3 (enExample)
WO (1) WO2017088839A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107778336B (zh) * 2016-08-24 2022-09-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的结晶形式
CN108239123B (zh) * 2016-12-27 2021-08-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的共晶、制备方法和应用
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
CN110407891A (zh) * 2019-07-31 2019-11-05 扬子江药业集团北京海燕药业有限公司 一种sglt-2抑制剂中间体的精制方法
CN114796250A (zh) * 2021-01-27 2022-07-29 宜昌东阳光长江药业股份有限公司 一种含有吡喃葡萄糖基衍生物的药物组合物
WO2022204907A1 (en) * 2021-03-30 2022-10-06 Sunshine Lake Pharma Co., Ltd. Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative
CN115141235B (zh) * 2021-03-30 2024-08-09 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的l-焦谷氨酸共晶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2015027963A1 (zh) * 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
ES2605886T3 (es) * 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
WO2016173425A1 (en) * 2015-04-30 2016-11-03 Sunshine Lake Pharma Co., Ltd. A glucopyranosyl derivative and preparation method and uses thereof

Also Published As

Publication number Publication date
HK1254667A1 (en) 2019-07-26
JP6916180B2 (ja) 2021-08-11
CA3005920C (en) 2023-08-22
CA3005920A1 (en) 2017-06-01
CN106810582A (zh) 2017-06-09
CN106810582B (zh) 2019-12-31
EP3371199B1 (en) 2024-12-25
US10555930B2 (en) 2020-02-11
AU2016360634B2 (en) 2020-05-21
AU2016360634A1 (en) 2018-06-07
EP3371199A1 (en) 2018-09-12
EP3371199A4 (en) 2019-06-12
WO2017088839A1 (en) 2017-06-01
US20180344689A1 (en) 2018-12-06
JP2018535237A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
ES3005482T3 (en) A complex of a glucopyranosyl derivative and preparation method and use thereof
CN107698569B (zh) 作为jak抑制剂的联吡唑衍生物
KR101971387B1 (ko) Ask1 억제제의 고체 형태
WO2022100623A1 (zh) 氮取代杂环噻吩类化合物及其用途
CN108239123B (zh) 吡喃葡萄糖基衍生物的共晶、制备方法和应用
CN106674294B (zh) 吡喃葡萄糖基衍生物的结晶形式
CN104053439A (zh) 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂
TWI822666B (zh) Janus激酶抑制劑之結晶型
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
JP2018537486A (ja) キノロン類似体及びその塩の結晶形
CN107778336B (zh) 吡喃葡萄糖基衍生物的结晶形式
EP4635947A2 (en) Crystal form of glucopyranosyl derivative and use thereof
CN118206518A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
HK1254667B (en) A complex of a glucopyranosyl derivative and preparation method and use thereof
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途
US20250074892A1 (en) Carbonyl bridged heterocyclic compound, and composition and application thereof
CN106674245B (zh) 吡喃葡萄糖基衍生物的制备及医药上的应用
CN118206517A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
CN118206516A (zh) 吡喃葡萄糖基衍生物的共晶及其用途
CN116437917A (zh) Atx抑制剂氘代衍生物及其应用
HK40115319A (en) Carbonyl bridged heterocyclic compound, and composition and application thereof
KR20170115315A (ko) 신규한 헤테로사이클릭 유도체 및 이들의 용도
WO2017128042A1 (zh) 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途